NCT06574620

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

Accelerating the Actionability of Treatment in Resected and Locally Advanced Pancreatic Cancer

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: British Columbia Cancer Agency · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: * Is it feasible to obtain genetic test results within a timeframe that can help inform treatment decisions for individuals with PDAC? * Can the genetic test results provide information about how a tumour will respond to or resist treatment? Participants will: * Receive standard chemotherapy to treat their cancer. * Provide samples of their blood, tissue, and fluid for genetic testing. * Visit the clinic every 4 weeks for check-ups and tests. * Complete questionnaires every 12 weeks.

Conditions

• Pancreatic Ductal Adenocarcinoma
• Resectable Pancreatic Ductal Adenocarcinoma
• Borderline Resectable Pancreatic Ductal Adenocarcinoma
• Locally Advanced Pancreatic Ductal Adenocarcinoma

Interventions

Type	Name	Description
GENETIC	Genetic testing	Analyses of the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins, and other molecules in the sample.
PROCEDURE	Optional biopsy	Optional collection of tumour tissue and normal tissue after the last dose of treatment.
PROCEDURE	Tissue collection	Collection of tumour tissue and normal tissue from biopsy or standard resection surgery prior to the first dose of treatment.

Timeline

• Start date: 2025-11-28
• Primary completion: 2028-12-01
• Completion: 2031-12-01
• First posted: 2024-08-28
• Last updated: 2026-01-16

Locations

1 site across 1 country: Canada